Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277769 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

708

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: Dupilumab
DRUG: Placebo (for Dupilumab)

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]